Application of aluminum adjuvant in preparation of tumor interventional ablation enhancer

By combining aluminum adjuvant with radiofrequency ablation technology, heating and adsorbing antigens form an in situ vaccine, the poor ablation and recurrence of lung cancer in RFA treatment were solved, and a more efficient and lasting tumor suppression effect was achieved.

CN118903405APending Publication Date: 2024-11-08ZHEJIANG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411277440.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-12
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Single radiofrequency ablation (RFA) treatment cannot effectively control the comprehensive ablation of lung cancer and prevent recurrence, and the effect is limited and the effect duration is short.

Method used

Aluminum adjuvant is used in combination with radiofrequency ablation technology, and in situ vaccine is formed by heating and adsorbing of antigens through aluminum adjuvant to enhance the antitumor immune response and prolong the therapeutic effect.

Benefits of technology

It significantly improves the thermal ablation effect of radiofrequency ablation, extends the durability of the therapeutic effect, effectively inhibits the recurrence of tumors, and provides an innovative and safe tumor treatment method.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005040645750000011
    Figure HDA0005040645750000011
  • Figure HDA0005040645750000012
    Figure HDA0005040645750000012
  • Figure HDA0005040645750000021
    Figure HDA0005040645750000021
Patent Text Reader

Abstract

The invention discloses an application of an aluminum adjuvant in preparation of a tumor interventional ablation enhancer, the aluminum adjuvant and radiofrequency ablation (RFA) are combined for use for the first time, and the aluminum adjuvant has the potential of increasing the therapeutic efficacy of the RFA, so that the aluminum adjuvant has the potential of being used as an RFA increasing agent. After RFA kills tumors, the aluminum adjuvant adsorbs antigens, vaccines are formed in situ, the organism is stimulated to generate targeted immune killing, and the effect of inhibiting the tumors is achieved. The aluminum adjuvant is used for improving the thermal ablation curative effect, the treatment mode is innovative, high feasibility is achieved, long-term clinical use can be achieved, high safety is achieved, good industrialization prospects are achieved, and great transformation potential is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

(I) Technical field

[0001] The present invention relates to the use of an aluminum adjuvant in the preparation of a tumor interventional ablation enhancer. The aluminum adjuvant is used in combination with an interventional tumor ablation technique to enhance the thermal ablation effect and induce anti-tumor immune effect therapy at the tumor site, thereby achieving a highly efficient tumor inhibition effect. (II) Background technology

[0002] As the main treatment method in interventional therapy, radiofrequency ablation (RFA) therapy can reduce the size of tumors, nodules or other types of growths in the body by heating tissues to cause cell death. Therefore, RFA is widely used in the treatment of diseases, including benign and malignant tumors, as well as other diseases such as chronic venous insufficiency in the legs and chronic pain. Based on the good results of RFA in the treatment of liver cancer, RFA was gradually applied to the clinical treatment of lung cancer in 2000 and showed good therapeutic effects. Studies have found that RFA treatment of stage I NSCLC patients who are not suitable for surgical resection can achieve good long-term treatment effects, increasing the 5-year survival rate and median survival time to 42% and 59 months. Although minimally invasive interventional lung tumor RFA treatment has the advantages of less trauma, good treatment effect and fast recovery, this treatment plan also has potential risks. For example, the heterogeneity of cancerous tissue components (such as differences in tumor tissue density, fibrosis or calcification) and blood flow will cause changes in electrical conductivity and thermal conductivity during RFA tumor ablation, thereby affecting the heating effect on cancer tissue and ultimately causing incomplete ablation. Therefore, approximately 31–42% of patients experience local progression after RFA treatment, accompanied by later tumor recurrence. Although repeated use of RFA can inhibit local progression after the first treatment to a certain extent, this method is only for some categories of tumors, and limited physical ablation cannot effectively control late recurrence. It can be seen that a single RFA treatment cannot meet the therapeutic effect of eradicating lung cancer.

[0003] In previous clinical studies and applications, the use of FDA-approved aluminum salt adjuvants (which have been widely used in vaccines such as diphtheria, pertussis, and tetanus vaccines, pneumococcal conjugate vaccines, hepatitis B, and COVID-19 vaccines) can absorb antigens and induce specific immune responses. However, it is not yet known whether aluminum salt adjuvants can be used to enhance the therapeutic effect of RFA. (III) Summary of the invention

[0004] The purpose of the present invention is to provide an application of an aluminum adjuvant in the preparation of a tumor intervention ablation enhancer. The aluminum adjuvant is used in combination with an RFA needle to significantly sensitize and warm RFA, and induce the formation of an aluminum adjuvant-based in situ tumor therapeutic anti-tumor preparation, which produces a highly efficient immunotherapy effect, solves the difficult problems of limited effect, short effect duration and easy tumor recurrence in tumor intervention thermal ablation treatment, achieves a comprehensive inhibitory effect on tumors, and provides a new treatment procedure and a new application of pharmaceutical excipients for improving the efficacy of thermal ablation for tumor treatment.

[0005] The technical solution adopted by the present invention is:

[0006] The present invention provides an application of an aluminum adjuvant in preparing a tumor intervention ablation enhancer.

[0007] Preferably, the aluminum adjuvant is a mixture of aluminum hydroxide and magnesium hydroxide, and the mass ratio of aluminum hydroxide to magnesium hydroxide is 1:2-0.1, preferably 1:1.

[0008] Preferably, the amount of aluminum adjuvant in the enhancer is 50-300 micrograms / 100 mm 3 Tumor, preferably 187.5 μg / 100 mm 3 Tumor.

[0009] Preferably, the tumor includes solid tumors such as liver cancer and lung cancer.

[0010] The present invention also provides an application of an aluminum adjuvant in the preparation of a post-RF ablation immunopotentiator, wherein the immunopotentiator is a preparation in which, after tumor ablation, the aluminum adjuvant adsorbs antigens to form a vaccine in situ to enhance the anti-tumor immune efficacy.

[0011] Compared with the prior art, the beneficial effects of the present invention are mainly reflected in:

[0012] (1) The present invention is the first to use aluminum adjuvants in combination with radiofrequency ablation. Aluminum salt adjuvants have the potential to enhance the therapeutic efficacy of RFA, and therefore have the additional potential to serve as RFA warming agents.

[0013] (2) After RFA kills the tumor, the aluminum adjuvant of the present invention adsorbs the antigen (protein) to form a vaccine in situ, stimulating the body to produce targeted immune killing, thereby achieving the effect of inhibiting the tumor and prolonging the duration of the RFA effect.

[0014] (3) The aluminum adjuvant used in the present invention improves the efficacy of thermal ablation, innovates the treatment procedure, has extremely high feasibility, can be used in the clinic for a long time, has extremely high safety, has good industrialization prospects, and has great transformation potential. (IV) Description of the drawings

[0015] Figure 1 The effect of aluminum adjuvant on the warming effect of RFA.

[0016] Figure 2 It is the effect of aluminum adjuvant on adsorbing protein (antigen).

[0017] Figure 3 This is a diagram showing the effect of combining aluminum adjuvant with RFA (lung cancer).

[0018] Figure 4 This is the effect diagram of the combined use of aluminum adjuvant and RFA (liver cancer). (V) Specific implementation methods

[0019] The present invention is further described below in conjunction with specific embodiments, but the protection scope of the present invention is not limited thereto:

[0020] The room temperature in the present invention refers to 25-30° C. The aluminum adjuvant (Alum) used in the embodiment of the present invention is a mixture of aluminum hydroxide and magnesium hydroxide in a mass ratio of 1:1.

[0021] Example 1: Effects of aluminum adjuvant on warming and ablation of RFA

[0022] PBS group: 5 mL of PBS (pH 7.4) was added to an open copper bowl, and the RFA needle (5 mm range) of the radiofrequency therapy device (Med Medical) was inserted into the copper bowl to form a pathway. The RFA power was set to 5 W, and the temperature of the RFA needle was recorded at 0s-60s with an infrared temperature camera (recorded every 5s);

[0023] PBS+aluminum adjuvant group: clean the copper bowl, add 1mL aluminum adjuvant solution (final concentration 2mg / ml or 4mg / ml, solvent is water) and 4mL PBS into the copper bowl, mix well, insert the RFA needle into the copper bowl to form a passage, set the RFA power to 5W, and use an infrared temperature camera to record the temperature of the RFA needle at 0s-60s (record every 5s). Results are shown in Figure 1 As shown, the results indicate that aluminum adjuvants can increase the temperature of radiofrequency ablation.

[0024] Example 2: Effect of aluminum adjuvant adsorption of protein (antigen)

[0025] Aluminum adjuvant (final concentration of 0.25 and 1.25 mg / mL) and bovine serum albumin (BSA, final concentration of 0.25 mg / mL) were added to PBS for incubation reaction. After 10 minutes, aluminum adjuvant and unadsorbed protein were separated by centrifugation at 20000g for 15 minutes. The supernatant was then recovered and the protein in the supernatant was quantified using the BCA detection kit, and the aluminum adjuvant protein adsorption efficiency was calculated. The results are shown in Figure 2 As shown, the results indicate that aluminum adjuvant can effectively adsorb BSA protein molecules, and through its own adjuvant effect and ability to adsorb antigens, it has the effect of forming an in situ vaccine.

[0026] Example 3. Therapeutic effect of aluminum adjuvant combined with RFA on liver cancer

[0027] Prepare 6-8 week old C57 / b6 female mice. Mice were subcutaneously injected with 2 million mouse liver cancer cells Hepa1-6. After about 2 weeks, subcutaneous tumors were formed, and the tumor size was ~400mm 3 .

[0028] The mice were randomly divided into 4 groups, 4 in each group. Group 1 was treated with RFA: the RFA needle was inserted into the tumor tissue and RFA ablation was performed (5W, 15-20s);

[0029] Groups 2-4 were treated with RFA+aluminum adjuvant: After the RFA needle was inserted into the tumor tissue and RFA ablation (5W, 15-20s) was performed, 250, 500, and 750 μg of aluminum adjuvant were injected into the tumor, dissolved in saline and injected. The rats were fed normally, and the tumor volume was measured every 2 days. The results are shown in Figure 3 , indicating that the combination of aluminum salt adjuvant and RFA can reduce tumor volume and effectively kill and inhibit tumor recurrence.

[0030] Example 4. Therapeutic effect of aluminum adjuvant combined with RFA on lung cancer

[0031] Prepare 6-8 week old C57 / b6 female mice. Mice were subcutaneously injected with 2 million mouse lung cancer cells LLC. Subcutaneous tumors formed about 2 weeks later, and the tumor size was ~400mm 3 .

[0032] Mice were randomly divided into 3 groups, 4 in each group. Group 1 was the control group: no treatment; Group 2 was treated with RFA: the RFA needle was inserted into the tumor tissue and RFA ablation was performed (5W, 15-20s); Group 3 was treated with RFA+aluminum adjuvant: the RFA needle was inserted into the tumor tissue and RFA ablation was performed (5W, 15-20s), and then 750μg of aluminum adjuvant was injected into the tumor after being dissolved in physiological saline. The mice were fed normally, and the tumor volume was measured every 2 days. The results are shown in Figure 4 , indicating that the combination of aluminum adjuvant and RFA can reduce tumor volume and effectively kill and inhibit tumor recurrence.

Claims

1. Application of an aluminum adjuvant in the preparation of a tumor intervention ablation enhancer.

2. The use according to claim 1, characterized in that The aluminum adjuvant is a mixture of aluminum hydroxide and magnesium hydroxide.

3. The use according to claim 2, characterized in that The mass ratio of the aluminum hydroxide to the magnesium hydroxide is 1:2-0.

1.

4. The use according to claim 1, characterized in that The tumors include liver cancer and lung cancer.

5. Use of the aluminum adjuvant according to claim 1 in the preparation of a post-radiofrequency ablation immunopotentiator.

6. The use according to claim 5, characterized in that The immunopotentiator is a preparation in which, after tumor ablation, aluminum adjuvant absorbs antigens to form a vaccine in situ and enhance the anti-tumor immune efficacy.